We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Melinta Therapeutics Inc | NASDAQ:MLNT | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.50 | 0.51 | 0.5198 | 0 | 00:00:00 |
FORM 3
| Washington, D.C. 20549 |
OMB APPROVAL
OMB Number: 3235-0104 Estimated average burden hours per response... 0.5 |
| |
1. Name and Address of Reporting Person * Blum Susan |
2. Date of Event Requiring Statement (MM/DD/YYYY)
| 3. Issuer Name and Ticker or Trading Symbol MELINTA THERAPEUTICS, INC. /NEW/ [MLNT] |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director _____ 10% Owner ___X___ Officer (give title below) _____ Other (specify below) VP of Finance & CAO / | ||
5. If Amendment, Date Original Filed(MM/DD/YYYY) | 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Beneficially Owned | |||
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
Melinta Common Stock | (1) | 3/21/2026 | Melinta Stock Option (right to buy) | 877.0 | $190.0 | D | |
Melinta Common Stock | (2) | 8/7/2027 | Melinta Stock Option (right to buy) | 80.0 | $104.85 | D | |
Melinta Common Stock | (3) | 4/19/2028 | Melinta Stock Option (right to buy) | 4000.0 | $37.25 | D | |
Melinta Common Stock | (4) | (4) | Melinta Restricted Stock Units | 25000.0 | (4) | D |
Reporting Owners | |||||
Reporting Owner Name / Address | |||||
Director | 10% Owner | Officer | Other | ||
Blum Susan C/O MELINTA THERAPEUTICS, INC. 300 TRISTATE INTERNATIONAL, SUITE 272 LINCOLNSHIRE, IL 60069 | VP of Finance & CAO |
Signatures | ||
/s/ Russell E Causey, by Power of Attorney | 10/25/2019 | |
**Signature of Reporting Person | Date |
1 Year Melinta Therapeutics Chart |
1 Month Melinta Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions